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Original Clinical Science—Liver

Design, Analysis, and Pitfalls of Clinical Trials Using
Ex Situ Liver Machine Perfusion: The International
Liver Transplantation Society Consensus Guidelines
Paulo N. Martins, MD, PhD,1 Michael D. Rizzari, MD,2 Davide Ghinolfi, MD, PhD,3
Ina Jochmans, MD, PhD,4,5 Magdy Attia, MD,6 Rajiv Jalan, MD, PhD,7 and Peter J. Friend, MD8

Background. Recent trials in liver machine perfusion (MP) have revealed unique challenges beyond those seen in most
clinical studies. Correct trial design and interpretation of data are essential to avoid drawing conclusions that may compromise patient safety and increase costs. Methods. The International Liver Transplantation Society, through the Special
Interest Group “DCD, Preservation and Machine Perfusion,” established a working group to write consensus statements
and guidelines on how future clinical trials in liver perfusion should be designed, with particular focus on relevant clinical
endpoints and how different techniques of liver perfusion should be compared. Protocols, abstracts, and full published
papers of clinical trials using liver MP were reviewed. The use of a simplified Grading of Recommendations Assessment,
Development, and Evaluation working group (GRADE) system was attempted to assess the level of evidence. The working group presented its conclusions at the International Liver Transplantation Society consensus conference “DCD, Liver
Preservation, and Machine Perfusion” held in Venice, Italy, on January 31, 2020. Results. Twelve recommendations were
proposed with the main conclusions that clinical trials investigating the effect of MP in liver transplantation should (1) make
the protocol publicly available before the start of the trial, (2) be adequately powered, and (3) carefully consider timing of
randomization in function of the primary outcome. Conclusions. There are issues with using accepted primary outcomes
of liver transplantation trials in the context of MP trials, and no ideal endpoint could be defined by the working group. The
setup of an international registry was considered vital by the working group.

(Transplantation 2021;105: 796–815).

INTRODUCTION
Machine perfusion (MP) preservation has been 1 of the
most promising concepts in liver transplantation in the last
20 years.1-19 Following extensive preclinical work,20 liver
MP entered the clinical arena a decade ago. To date, very
few clinical trials have been published and the superiority
of liver MP as a preservation method versus static cold
storage is not yet established. Clinical trials investigating
liver MP pose challenges beyond those of most clinical
studies. Optimal trial design and interpretation of data
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may avoid incorrect conclusions that compromise patient
safety, increase costs, and delay advancement of the science
in the field.21-31
The International Liver Transplantation Society
(ILTS) through the Special Interest Group (SIG) “DCD,
Preservation and Machine Perfusion” established a working group to discuss the relevant literature and establish
consensus statements and suggestions regarding how
future clinical trials in liver perfusion should be designed,
with particular focus on relevant clinical endpoints and
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how different techniques of liver perfusion should be compared. The Working Group presented the discussion at the
ILTS consensus conference “DCD, Liver Preservation, and
Machine Perfusion” consensus conference held in Venice,
Italy, on January 31, 2020. This article describes the process followed by the Working Group and summarizes the
discussion, recommendations, and guidelines it established.
METHODOLOGY
Early in 2019, the recently created ILTS SIG “DCD,
Preservation and Machine Perfusion” received the task
from the ILTS to establish a working group to discuss the
relevant literature on “Clinical trials design in MP” and to
write consensus statements and guidelines and assess the
level of evidence. The ILTS and SIG “DCD, Preservation,
and Machine Perfusion” leaderships selected a group of
7 ILTS members (all authors of this article). They were
approached by the steering committee of the SIG and chosen based on their previous experience with MP experience
and geographic distribution. All, except 1 (Rajiv Jalanhepatologist), are transplant surgeons.
The working group was asked to consider the following
questions regarding the design of clinical trials assessing
liver MP:
1. Which preservation techniques should be compared in the
next randomized trials?
2. What are clinically relevant trial endpoints?
3. Which grafts should be included?
4. Update on clinical trials

The expectation was to rate the level of evidence
based on the Grading of Recommendations Assessment,
Development and Evaluation working group (GRADE)
system (Table 1), classifying it as strong, conditional, or
not recommended (class 1–3), according to the level of evidence (level A to C), balance between patient benefit and
harm, significance to patients, and cost-effectiveness http://
www.gradeworkinggroup.org)32 (Table 1).
The working group members identified published clinical trials investigating liver MP by using a PubMed search
using keywords: liver MP, clinical trial, machine preservation, and searching open source platforms for trial registries
(clinicaltrials.gov, EudraCT, ChiCTR). We also included
metanalysis and cross-references from those articles.33-35
These were shared via a cloud platform and discussed via
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email and 2 conference calls in the months preceding the
final meeting in Venice, Italy. The results were presented to
the delegates of the ILTS “DCD, Liver Preservation, and
Machine Perfusion” consensus conference held in Venice,
Italy, on January 31, 2020. The presentation is available
for ILTS members online (at https://ilts.org/education/
lectures/machine-perfusion-and-clinical-trials-sessionspecial-considerations-and-pitfalls-in-clinical-trials-usingmachine-perfusion/)
The ILTS invited 36 faculty that are experts in the field
of DCD liver transplantation and MP transplantation (for
a complete list and biography of invited faculty, please
refer to https://s3.amazonaws.com/wp-ilts-media/wp-content/uploads/2020/01/29161208/02-Final-ILTS-Venice2020-Meet-The-Faculty.pdf). The meeting was attended
by 151 delegates from 25 countries.
After receiving feedback from the audience, a meeting
was held with input from our working group (authors)
and 15 delegates of different institutions, who voluntarily
participated in this discussion group (list under acknowledgments). Data were discussed again in detail, and we
established our consensus statements, level of evidence,
and future recommendation guidelines.
After the consensus meeting, we discussed the article
drafting through emails, edited using a cloud platform,
and the final version was approved by all authors, the SIG,
and ILTS leadership.
CHALLENGES IN LIVER MACHINE PERFUSION
CLINICAL TRIAL DESIGN
Power and Primary Endpoints

It is very important when designing clinical trials to
choose the appropriate primary endpoints.21,23,30,36-38 The
choice of endpoint can have a significant bearing on the
study conclusions.39-42 The primary endpoint needs to be
clinically meaningful, and 1 should realize that a randomized controlled trial (RCT) can only be powered on 1
primary endpoint. Secondary endpoints are often defined
as well, although the sample size is often too small for the
analyses of the secondary endpoints to reach sufficient
power. To reduce the potential for selective posttrial reporting and multiple testing, pretrial objective definition and
reporting (eg, ClinicalTrials.gov) of the primary endpoint
for which RCT is designed are strongly recommended.25,28
The sample size calculation for an RCT is based on the

TABLE 1.

Simplified grading system of clinical evidence according to the GRADE system (http://www.gradeworkinggroup.org)
Level of evidencea

Confidence in the evidence

High

Further research is unlikely to change our confidence in the estimate of
benefit and risk
Further research (if performed) is likely to have an impact on our confidence
in the estimate of benefit and risk and may change the estimate
Any estimate of effect is uncertain

Moderate
Low

Data derived from meta-analyses or systematic
reviews or from (multiple) RCTs with high quality
Data derived from a single RCT or multiple
nonrandomized studies
Small studies, retrospective observational studies, registries

Grade of recommendationb (wording associated with the grade of recommendation)

Strong
Weak

“Must,” “should,” or “ILTS recommends”
Can,” “may,” or “ILTS suggests

According to Guyatt GH et al.32
a
Level was downgraded if there was poor quality, strong bias or inconsistency between studies; level was upgraded if there was a large effect size.
b
Recommendations were reached by consensus of the panel and included the quality of evidence, presumed patient-important outcomes and costs.
ILTS, International Liver Transplantation Society; RCT, randomized controlled trial.
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primary endpoint and includes a number of assumptions.
The sample size calculation is essential to make sure that
a statistically significant and clinically relevant difference
can be detected with a high probability.
Trials in transplantation are particularly challenged by
the difficulty to power studies for conventional “hard”
endpoints such as graft loss and patient death in the first
year because these events are uncommon, requiring very
large numbers of patients.21,38
One way to overcome such a limitation is to focus the
trial on a subgroup of subjects that are at higher risk to
develop the event. Indeed, as the safety of liver MP is
becoming established, it is now possible to design clinical
trials that use extended-criteria grafts (DCD, older donors,
steatotic grafts).43,44 As these grafts have higher overall
complication rates, with increased incidences of graft loss,
ischemic type biliary injury (ITBL), primary nonfunction
(PNF), or death in the first year, the sample size needed to
show a clinically meaningful difference would be smaller
than for trials including all donor types. There are important caveats to such an approach. There is no universal
definition of extended-criteria donors. In addition, there
are often concerns that trial participants are not a representative sample of the whole population because of stringent inclusion and exclusion criteria. External validation
of findings also implies that the findings of a study will be
applicable across the intended populations. The ability to
make reliable statements about a broad population usually
considers that the study groups represent a random sample from the population and comparisons of study arms
assume that subjects are equally likely to be included in
either arm.44 Speich et al showed that in surgical RCTs,
sample size calculation was only adequately reported in
53% of the cases.31
Trials in transplantation are often limited to the use of
intermediate endpoints based on time and resource constraints unless intermediate endpoints have been validated
and have independent clinical advantage (eg, improved
graft function, fewer complications, lower cost); caution
must be exercised in extrapolating results to an important
long-term clinical finding (eg, graft and patient survival,
biliary complications).21,23,37,38
Surrogate Endpoints (Laboratory Biomarkers)

A surrogate endpoint has been defined as “a biomarker
that is intended to substitute for a clinical endpoint and
generally is considered valid given a more rapid and frequent incidence and strong association with traditional
endpoints.”37 The use of parameters more likely classified
as intermediate endpoints, defined as a characteristic that
is intermediate in the causal pathway between an intervention and the clinical endpoint, have become common
substitutes for true surrogates. The primary limitation of
intermediate endpoints is that they may not be predictive
of the most important clinical endpoints (eg, graft loss).21,37
To find statistical significance in a laboratory parameter
without clear clinical significance may be meaningless.
Many surrogate markers of liver graft viability and
injury have been utilized, however whether they are adequate predictors of long-term graft outcomes remains a
topic of debate. None of them has been strongly validated
in the clinical setting.46,47 The ideal biomarker would be
specific, easily processed and inexpensive with a quick

“turn around” time that could be available before transplantation.48 It would also have to predict long-term
clinically relevant outcomes with a high degree of precision. Unfortunately, in MP trials, no single parameter (or
combination of parameters) has been clearly established
that meets strong criteria as a surrogate endpoint.46-48
Additionally, MP introduces many variables that may
affect intra- and postoperative parameters. For example,
size of the liver, volume of perfusate, and temperature of
perfusion may all impact on machine and even postreperfusion transaminases levels.
Composite Endpoints

To decrease the need of large sample size and to increase
trial efficiencies in transplantation, a common strategy is
the utilization of composite endpoints, which typically
consist of selective adverse events, patient deaths, and graft
losses. It has been suggested the use of the “comprehensive
complication index” as primary endpoint, which is currently often used in surgery and transplantation with the
availability of reference values provided in a recent multicenter benchmark study covering 1 year after transplantation.36,43 Biochemical composite endpoints have been used
in most MP trials as EAD scores. Clinical composite endpoints have already been used in a lung MP preservation
trial.49
One limitation of these endpoints is the presumption of
equivalent severity of individual outcomes. Trials utilizing
composite endpoints should report distinct event rates for
each component, but the interpretation of results should
not extend to individual outcomes.
RESULTS
Summary of Clinical Trials

We analyzed the literature on clinical trials using liver
MP (Tables 2 and 3). The majority of study protocols had
been made public in advance in an open access registry of
clinical studies (clinicaltrials.gov, EudraCT, ChiCTR). Most
published studies were single center and had a small sample
size and therefore likely underpowered. Several studies did
not provide detailed description of the study, and nomenclature was not uniform. Only 2 papers were randomized
and both used NMP.50,51 A number of ongoing randomized
studies had not been completed or published at the time
this article was prepared. Follow-up was short (all these
studies had an overall median follow-up <1 y).
In addition to the published NMP clinical trials, there
are currently at least 10 ongoing clinical trials in clinicaltrials.gov and others in national registries. In addition to
the published HMP clinical trials, there are at least 9 ongoing clinical trials (Tables 2 and 3).
Regarding the GRADE system classification of clinical
evidence, our group agreed that the level of evidence for
all questions is generally low.
1. Does machine preservation provide better outcomes compared with standard cold static preservation?

We were not able to reliably and systematically answer
this question based on GRADE system because this would
require much more complexes analysis of all complications and outcomes. There are only 2 published RCTs in
NMP of the liver, both of which suggest positive evidence,

Copyright © 2021 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

TABLE 2.

Trial name: HOPE with
cytokine filtration in liver
transplantation (Cyto-HOPE)
NCT04203004
PI: Stefania Camagni,
Bergamo, Italy
Trial name: HOPE for extended
criteria donors in liver
transplantation (HOPEext)
NCT03929523
PI: Mickael Lesurtel, Lyon,
France
Trial name: Clinical trial of new
HOPE system vs SCS
NCT03837197
PI: Matteo Ravaioli, Bologna, Italy
Trial name: Post-SCS HOPE in
Bergamo Liver Transplant
Program
NCT03098043
PI: Stefania Camagni,
Bergamo, Italy
Trial name: Study to evaluate
performance of LifePort
liver transporter system, a
machine perfusion system,
for liver transplant (PILOT)
NCT03484455
Organ recovery systems
Trial name: DHOPE of DCD
liver grafts in preventing
biliary complications after
transplantation (DHOPE-DCD)
NCT02584283
PI: Robert Porte, Groningen, The
Netherlands

Author

Not
reported

DBD

DBD

DCD/DBD

Not
reported

DCD

Estimated
completion
2022

Estimated
completion
date 2022

Estimated
completion
date 2021

Estimated
completion
date 2021

Estimated
completion
date 2021

Completion
date: 2019

Y

Donor type
(DCD/DBD)

156
(78/78)

140

20

110

266
(133/133)

20
(20/0)

No. total
(HMP/
SCS)

Clinical trials on ex situ liver hypothermic machine perfusion

Device: Liver Assist
HA 25 mm Hg/PV 5
mm Hg.
0.5 mL/min 100% O2
Time on machine: 2 h

Device: LifePort liver
transporter.

Device not reported.
HA 25-30 mm Hg/PV <5
mm Hg.
Time on machine: 1 h.
Oxygenated (50–70 kPa)

Device not reported.
Oxygenated (500–600
mm Hg).

Device: Liver assist.
PV only.
Time on machine: 1–4 h.

Device not reported.
HA <30 mm Hg/PV <5
mm Hg.
Time on machine: 4 h

Perfusion characteristics

UW-MPS

Results
awaited

Results
awaited

Results
awaited

UW-MPS

Vasosol

Results
awaited

Results
awaited

Results
awaited

UW-MPS

UW-MPS

UW-MPS

Perfusate

Total time of
preservation
(min) (range)

Primary: incidence of NAS at 6 mo
Secondary: graft/patient survival,
PNF, IPF, recipient hemodynamics
during LT, hospital length of stay,
postoperative complications, liver
function and injury markers, costs
of treatment, quality of life.

Primary: Incidence of EAD
Secondary: MEAF score, L-GrAFT,
metabolic profiling, PRS. 90-d
morbidity/mortality, length of hospital
stay, MCRP within 1 y, 3-mo/1-y
graft/patient survival, hospital costs
Primary: incidence of EAD
Secondary: surgical complications,
liver function at 6/12 mo, patient
survival at 6/12 mo
Primary: incidence of EAD
Secondary: Dindo-Clavien
complications, ischemic
cholangiopathy, length of hospital
stay, 30-d/1-y graft/patient
survival,
Primary: incidence of EAD

Primary: Incidence of PRS
Secondary: Entity of IRI, incidence of
EAD

Endpoints

Martins et al
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Results awaited

Results awaited

Results awaited

Results awaited

Results awaited

Results awaited

Outcome (HMP vs SCS)
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DBD

DBD

HMP 10/0
SCS 20/0

Completion
date: 2019

Completion
date: 2018

2017

2015

2015

Dutkowski et al109

Guarrera et al110

HMP 0/31
SCS 0/30

61
(31/30)

75
(25/50)

30
(10/20)

10
(10/0)

25
(25/0)

46
(23/23)

No. total
(HMP/
SCS)

Device: ECOPS device
PV 120-180 mL/min
Oxygenated
time on machine: 118 min
(101–149)
Device: Medtronic PBS
0.667 mL/g/liver/min
No active oxygenation
Time on machine:
258 ± 54 min

Device: LiverAssist
HA 20–30 mm Hg/PV 5
mm Hg.
500 mL/min 100% O2
Time on machine:
126 min (123–135)

Device: Exiper, Bologna
machine perfusion
oxygenated (80–100 kPa)
Time on machine: 2 h

Device not reported.
PV <3 mm Hg.
Oxygenated (40 kPa)
Time on machine: 2 h

Device: Liver Assist
PV <3 mmHg.
Oxygenated (150200 mmHg)
Time on machine: 1 h

Perfusion characteristics

Results
awaited

HMP: 521
(469–592)
SCS: 503
(476–526)

Not reported

UW-MPS

Vasosol

HMP:
564 ± 96
SCS:
534 ± 144

HMP: 317
(280–391)
SCS: 395
(349–447)

Results
awaited

UW-MPS

KPS-1

Results
awaited

IGL-1

Perfusate

Total time of
preservation
(min) (range)
Outcome (HMP vs SCS)
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100% vs 80% 6-mo graft survival,
100% vs 67% 1-y graftt
survival. 100% vs 85% 1-y
patients survival.
No technical problems.
Peak ALT (IU/L): 966 vs 1858.
NAS: 0/10 vs 5/20.
Ischemic cholangiopathy:
0% vs 22%.
Biliary complications: 20% vs 46%.
Peak ALT (IU/L): 1239 vs 2065.
90% vs 69% 1-y graft survival.
PNF: 3% vs 7%. EAD: 19% vs 30%.
Vascular complications:
9% vs 7%.
84% vs 80% 1-y patient survival.
Biliary complications: 4/31 vs 13/30/
AKI: 10% vs 27%.
Hospital stay: 13.6 vs 20.1 d.
Primary: graft survival at 6 mo.
Secondary: 1-y graft/patient survival,
technical safety, perfusate
microbiology, postoperative
complications

Primary: incidence and severity of
biliary complications within 1 y
after LT.
Secondary: liver IRI and function, graft
survival
Primary: incidence of PNF, EAD and
vascular complications, 1-y graft/
patient survival.
Secondary: incidence of biliary
complications, AKI, hospital length
of stay, liver/kidney function
markers

Results awaited

Results awaited

Primary: graft function at 3 mo
Secondary: graft/patient survival at
3 mo

Primary: incidence of PNF/EAD.
Secondary: nr of intraoperative
transfusions, PRS, morbidity on d
7, graft survival at 3 mo, hospital
length of stay, cost of initial stay,
cost of the hospitalization stay

Primary: postoperative peak ALT in the Results awaited
first postoperative wk.
Secondary: Dindo/Clavien
classification, hospital- and ICU
stay, IRI, 1-y patient/graft survival

Endpoints

Transplantation

HMP 25/0
SCS 50/0

DBD

Completion
date: 2019

Y

Donor type
(DCD/DBD)

Trial name: HOPE for Human
ECD and DBD Liver
Allografts (HOPE-ECD-DBD)
NCT03124641
PI: Georg Lurje (Aachen,
Germany)
Trial name: Interest of
oxygenated hypothermix
perfusion in preservation
of hepatic grafts from ECD
(PERPHO)
NCT03376074
Renes University Hospital
Trial name: HOPE vs SCS for
Margina Graft (PIO)
NCT03031067
PI: Matteo Ravaioli, Bologna,
Italy
Van Rijn et al108

Author

TABLE 2. (Continued)
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2010

Y

HMP 0/20
SCS 0/20

Donor type
(DCD/DBD)

40
(20/20)

No. total
(HMP/
SCS)

Device: Medtronic PBS
0.667 mL/g/liver/min
No active oxygenation
Time on machine:
228 ± 54 min

Perfusion characteristics

Vasosol

Perfusate

HMP:
558 ± 126
SCS:
516 ± 168

Total time of
preservation
(min) (range)

Primary: incidence of PNF, EAD and
vascular complications, 1-y graft/
patient survival.
Secondary: incidence of biliary and
vascular complications, AKI,
hospital length of stay, liver/kidney
function markers

Endpoints

No PNF in either group.
EAD: 5% vs 25%.
No vascular complications in either
group.
90% vs 90% 1-y graft/patient
survival.
Biliary complications: 2/20 vs 5/20.
Hospital stay: 10.9 vs 15.3 d.
Peak ALT (IU/L): 560 vs 1358

Outcome (HMP vs SCS)

Y

Trial name: Safety and Ongoing
completion
feasibility of NMP
date: 2023
to preserve and
evaluate orphan
livers
NCT03456284
PI: Cristiano Quintini,
The Cleveland Clinic
Ongoing
Trial name:
Efficacy of Ex situ NMP completion
date: 2023
vs cold storage in
the transplant with
steatotic liver graft
(ORGANOXLAFE)
NCT03930459
Instituto de
Investigacion
Sanitaria La Fe

Author

15

50

Results
awaited

No. total
(NMP/SCS)

Results
awaited

Donor type
DCD/DBD

Device:
not reported.

Device: institutional liver MP
device

Perfusion characteristics

Clinical studies on ex situ liver normothermic machine perfusion

TABLE 3.

Not reported

Not reported

Perfusate

Results
awaited

Results
awaited

Total time of
preservation
(min) (range)

Results awaited

Continued next page

Outcome (NMP vs SCS)

Primary: Peak of AST and ALT Results awaited
at 1, 3, 5, 7 d post-LT
Secondary: PNF, graft/patient
survival at 30 d, 6/12 mo,
PRS, EAD, liver function and
injury markers, hospital/
ICU stay, RRT, intraop
thromboelastogram result,
biliary stenosis in MRS
evidence

Primary: 30 d
posttransplantation rate of
survival and PNF
Secondary: EAD, 6 mo graft
survival, liver function, and
injury markers

Endpoints

AKI, acute kidney injury; C, control; D, duration; DBD, donation after brain death; DCD, donation after circulatory death; DHOPE, dual hypothermic oxygenated machine perfusion solution; EAD, early allograft dysfunction; ECD, extended criteria donor; HA, hepatic artery; HOPE,
hypothermic oxygenated machine perfusion; IGL-1, Institute George Lopez solution; IRI, ischemia-reperfusion injury; KPS-1, kidney perfusion solution; L-GrAFT, liver graft assessment following transplantation risk factor; LT, liver transplantation; MEAF, model of early allograft function;
MP, machine perfusion; NAS, non-anastomotic biliary strictures; PNF, primary nonfunction; PRS, postreperfusion syndrome; PV, portal vein; SCS, static cold storage. UW-MPS, University of Wisconsin machine perfusion solution.

Guarrera et al

Author

TABLE 2. (Continued)
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Trial name:
sequential hypo- and
normo-thermic
perfusion to
preserve extended
criteria donor livers
for transplantation
NCT04023773
PI: Cristiano Quintini,
The Cleveland Clinic
Trial name:
using ex vivo NMP
with the organox
metra device to
store human livers
for transplantation
NCT02478151
PI: David Grant,
University Health
Network, Toronto
Trial name:
Normothermic Liver
Preservation Trial
NCT03089840
PI: James Shapiro,
University of Alberta
Trial name:
Pilot Study to Assess
Safety and
Feasbility of NMP
in Human Liver
Transplantation
NCT02515708
PI: Cristiano Quintini,
The Cleveland
Clinic

Author

ECD

Results
awaited

Results
awaited

Results
awaited

Ongoing
Completion
date: 2021

Ongoing
Completion
date: 2021

Ongoing
Completion
date: 2020

Donor type
DCD/DBD

Ongoing
completion
date: 2022

Y

TABLE 3. (Continued)

25

50

Device:
Institutional Liver MP device

Device:
OrganOx metra

Device:
OrganOx metra

Device:
Institutional Liver MP device

Perfusion characteristics

Not reported

Not reported

Not reported

Not reported

Perfusate

Results
awaited

Results
awaited

Results
awaited

Results
awaited

Total time of
preservation
(min) (range)

Results awaited

Results awaited
Primary: incidence of EAD
Secondary: PNF, 6-mo graft/
patient survival, 7-d peak
liver function tests, intraop
flow measurement, PRS,
intraop surgical outcomes,
kidney failure, biliary/vascular
complications at 6mo,
hospital/ICU stay, rejection
rate at 6mo, opportunistic
viral infection rate
Continued next page

Outcome (NMP vs SCS)

Results awaited
Primary: incidence of PNF,
re-LT, survival at 3 mo
Secondary: Rate of device
failures resulting in organ
discard, recruitment
rates to study, IRI, graft
function, ability of perfusion
parameters to predict
clinical outcomes following
LT
Primary: 30-d graft survival
Results awaited
Secondary: 30-d patient
survival, EAD

Primary: Patient/graft survival
at 1 mo
Secondary: EAD, patient/graft
survival at 6 mo, blood
loss, liver function and
injury markers, hospital/ICU
length of stay

Endpoints

Transplantation

40

15

No. total
(NMP/SCS)

802
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Results
awaited

Results
awaited

Results
awaited

DHOPE-CORNMP 7/0

Ongoing
Completion
date: 2020

Ongoing
Completion
date: 2020

Ongoing
Completion
date: 2020

2019

Trial name:
Viability Testing and
Transplantation of
Marginal Livers
(VITTAL)
NCT02740608
PI: Darius Mirza,
University Hospital
Birmingham

Trial name:
TransMedics (OCS)
Liver PROTECT
NCT02522871
TransMedics
De Vries et al112

Y

Donor type
DCD/DBD

Trial name: WP01Normothermic
Liver Preservation
NCT02775162
PI: Stuart Knechtle,
Duke University

Author

TABLE 3. (Continued)

7 (7/0)

300

22

266

No. total
(NMP/SCS)

Device: Liver Assist
Pressure DHOPE:
HA: 11 mm Hg
PV: 5mmHG
Pressure NMP:
HA: 70 mm Hg
PV: 11 mm Hg
Flow NMP:
HA: 0.55 L/min (0.24-0.73(
PV: 1.7 L/min (01.46-1.74)

Device:
TransMedics OCS

Device:
OrganOx metra

Device:
OrganOx metra

Perfusion characteristics

HBOC-201

Not reported

Not reported

Not reported

Perfusate

Outcome (NMP vs SCS)

Results awaited
Primary: Incidence of EAD
Secondary: PNF, graft/patient
survival, PRS, liver function
and injury markers, biliary
complications, incidence
of livers randomized but
not transplanted, organ
utilization, healthcare costs,
quality of life measures
Primary: 90-d patient survival, Results awaited
use of NMP to identify the
proportion of transplantable
liver grafts from currently
rejected donor organ pool
Secondary: 12 mo liver graft
function, 90-d morbidity
associated with receipt
of extended criteria graft,
physiological response to
reperfusion of perfused
grafts
Primary: Incidence of EAD,
Results awaited
SAEs in first 30 d

Endpoints
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Total MP time: Primary: Graft survival at 3 mo 100% 3-mo graft survival
427
(283-517)

Results
awaited

Results
awaited

Results
awaited

Total time of
preservation
(min) (range)

© 2021 Wolters Kluwer
Martins et al

803

51

2019

2018

2018

2017

Nasralla et al50

Watson et al92

Watson et al93

2019

Y

12 (12/0)

47 (47/0)

221
(121/101)

105
(21/84)

20
(10/10)

No. total
(NMP/SCS)

Gelofusine (B
Braun) + 3-unit
donor-matched
PRBC

4 units blood
bank-obtained
FFP + 4 units
PRBC

Gelofusine
(B Braun) +
ABO-compatible
RBC concentrate

Perfusate

Leukocyte
Device: Liver Assist
depleted
Pressure:
red cells +
HA: 60 mm Hg
Gelofusine
PV: 8-10 mm Hg
(B Braun) or
Flow: not reported
Steen solution
Time on machine: 4 h
Leukocyte
Device: Liver Assist
depleted
Pressure:
red cells +
HA: 60 mm Hg
Gelofusine (B
PV: 8-10 mm Hg
Braun) or Steen
Flow: not reported
solution
Time on machine: 284 (122-530)

Device:
noncommercial, institutional
apparatus
Flow:
HA: 0.5 L/min
(0.2-0.7)
PV: 1.6 L/min
(1.1-2.1)
Time on machine:
3.35-7.89h
Device:
OrganOx metra
Flow:
HA ≈ 0.28 L/min
PV ≈ 1.1 L/min
Time on machine:
9.13h (1.42-24)

Device: LiverAssist
Flow:
HA: 0.205-0.420 L/min
PV: 1.1-1.7 L/min
Time on machine:
4.2h (3.25-4.7)

Perfusion characteristics

NMP: 778
(564-1561)

NMP:
460-1388

NMP: 714
(258-1527)
SCS:465
(223-967)

NMP: 528
(462-594)
SCS: 498
(408-588)

NMP: 246
(206-267)
SCS: 394
(366-465)

Total time of
preservation
(min) (range)
Outcome (NMP vs SCS)

Primary: Assessment of
viability in declined
marginal livers and
research livers
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5/6 developed PRS, 4 sustained
vasoplegia, 1 PNF, 3 DCD livers
developed cholangiopathy

No PNF in either group.
EAD: 2/10 vs 1/10.
Peak ALT (IU/L): 332 (263-610) vs 428
(303-1162).
Graft survival: 90% vs 100%.
Patient survival: 100% vs 90%.
Biliary complication: 1/10 vs 0/10.
No PNF in either group.
Primary: Safety, feasibility,
and impact on intrahepatic EAD: 19% vs 46.4%, P = 0.02.
Peak ALT (IU/L): 363 ± 318 vs 1021 ± 999.
hemodynamics of FFP
No cases of ischemic. cholangiopathy.
Secondary: Prove safety
Patient survival: NMP: 95.2%
and feasibility of
(One patient died of intracranial
a noncommercial,
hemorrhage on postoperative mo 8
institutional perfusion
with normal liver
apparatus
function). Mortality in the historical control
group not reported.
PNF: 0.8% vs 0%.
Primary: Peak level of serum
EAD: 10% vs 30%.
AST within 7 d after LT
Peak AST (IU/L): 488 (408.9-582.8) vs
Secondary: Organ discard
964 (794.5-1172.0).
rate, PRS, PNF, EAD, length
Patient survival at 1y: 95.8% vs 97%.
of hospital/ICU stay, RRT,
cholangiopathy on MRCP at Graft survival at 1y: 95% vs 96%.
6 mo, graft/patient survival
at 1 yr
Primary: observation of
22 livers were transplanted. 1 recipient
biochemistry and perfusion
died following PNF, 1 developed EAD,
characteristics
4 developed ITBL (3 required reLT).
Primary: Graft/patient survival
at 6 mo
Secondary: peak
transaminases within 7
d, biliary complications at
6 mo

Endpoints
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NMP 9/3

NMP 35/12

NMP 34/87
SCS 21/80

NMP 8/13
SCS 17/68

NMP 0/10
SCS 0/10

Donor type
DCD/DBD

Transplantation

Liu et al11

Ghinolfi et al

Author

TABLE 3. (Continued)
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2016

2016

Selzner et al115

Ravikumar et al116

NMP 4/16
SCS 8/32

NMP 2/8
SCS 8/24

NMP 4/2

NMP 4/6
SCS 8/22

Donor type
DCD/DBD

60
(20/40)

40
(10/30)

6 (6/0)

39
(10/30)

No. total
(NMP/SCS)

Device:
OrganOx metra
Pressure:
Not reported.
Flow:
Not reported.
Time on machine:
11.5h (3.3-22.5)
Device: Liver Assist, OrganOx
Pressure: not reported.
Flow:
HA: 0.53 L/min (0.36-0.62)
PV: 1.1 L/min (0.7-1.5)
Time on machine: 3 h
Device:
OrganOx metra
Pressure:
Not reported.
Flow:
HA: 0.3 L/min (0.2-0.4)
PV: 1.25 L/min (1.2-1.3)
Time on machine:
8h (5.7-9.7)
Device: OrganOx metra
Pressure:
HA 60-75mmHg
PV not reported.
Flow:
HA≈0.2 L/min
PV≈0.8 L/min
Time on machine:
9.3h (3.5-18.5)

Perfusion characteristics

3 units of crossmatched PRBC
+ 1 unit of
Gelofusine (B
Braun)

3-units PRBC +
Steen solution

Blood-based

Gelofusine (B
Braun) + 3-unit
type “O” PRBC

Perfusate

Not reported

NMP: 586
(221-731)
SCS: 634
(523-783)

NMP: 798
(724-951)

NMP: 786
(304-1631)
SCS:235
(64-890)

Total time of
preservation
(min) (range)

Primary: 30-d graft survival
Secondary: liver function
and injury markers within
7 d after LT, patient/graft
survival at 6 mo

Primary: assess safety and
feasibility of NMP

Primary: 30-d graft survival
Secondary: Patient survival
at d 30, peak AST within 7
d, EAD, liver function and
injury markers, ClavienDindo score, graft/patient
survival at 6 mo, biliary
complications at 6 mo.
Primary: Demonstrate
feasibility of rejected
allografts transplanted
following assessment and
resuscitation by NMP

Endpoints

No PNF in either grougs.
EAD: 15% vs 22.5%.
Peak AST (IU/L): 417 (84-4681) vs 902
(218-8786)/
30-d graft survival: 100% vs 97.5%.
6-mo patient survival: 100% vs 97.5%.

No PNF in either group.
EAD: 55.5% vs 29.6%.
Peak AST (IU/L): 1252 (383-2600) vs
839 (153-2600).
6-mo graft survival: 80% vs 100%
6-mo patient survival: 89% vs 100%
6-mo biliary complications 0% (0/8) vs
14.8% (4/27) P = 0.55.
Uneventful transplant procedure in all 5
transplanted patient and immediate
function recovery in all grafts.
Normalized liver tests at median
follow-up of 7mo. One graft did not
met viability criteria after 3 h of MP.
Peak ALT (IU/L): 619 (55-2858) vs 949
(233-3073).
3-mo graft/patient survival 100% in
both groups.

Outcome (NMP vs SCS)

Modified from Martins PN et al.88 References in this table include studies by Liu et al,11 Nasralla et al,50 Ghinolfi et al,51 Watson et al,92 Watson et al,93 De Vries et al,112 Bral et al,113 Mergental et al,114 Selzner et al,115 and Ravikumar et al.116
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C, control; C-NMP, continuous-normothermic machine perfusion; D, duration; DBD, donor after brain death; DCD, donor after circulatory death; EAD, early allograft dysfunction; ECD, extended
criteria donor; FFP, fresh frozen plasma; GGT, gamma-glutamyl transferase; HA, hepatic artery; HAT, hepatic artery thrombosis; ICU, intensive care unit; INR, international normalized ratio; IRI, ischemia-reperfusion injury; LT, liver transplantation; MAP, mean arterial pressure; MP,
machine perfusion; MRCP, magnetic resonance imaging scan of biliary tree; NCT, national clinical trial identifier; NEVLP, normothermic ex vivo liver perfusion; NMP, normothermic machine perfusion; PNF, primary nonfunction; POD, postoperative day; PRBC, packed red blood cells;
PRS, postreperfusion syndrome; pSCS, poststatic cold storage; PV, portal vein; RRT, renal replacement therapy; SAE, serious adverse event; SCS, static cold storage.

2016

2017

Y

Mergental et al114

Bral et al

Author

TABLE 3. (Continued)

© 2021 Wolters Kluwer
Martins et al

Copyright © 2021 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

805

806

Transplantation

www.transplantjournal.com

■ April 2021 ■ Volume 105 ■ Number 4

although further corroboration from other trials would be
desirable. None of the HMP trials in liver transplantation
have reported yet. It is too early, therefore, to provide a
definitive answer to this question.
2. What are clinically relevant trial endpoints?

The group agreed that, wherever possible, the use of
direct clinically relevant endpoints as the primary endpoint
is desirable (eg, 1-y graft survival, 1-y patient survival,
ITBL/biliary complication rates, length of stay, ICU stay,
acute kidney injury/ hemodialysis need, total complication
rate, mortality on the waitlist, organ utilization, overall
cost). We support the creation of an international registry
of all cases of MP (including in situ normothermic regional
perfusion as well as ex situ MP) in liver transplantation.
The rigorous analysis of a large and comprehensive registry database enables questions to be addressed that are
impractical as the objectives of randomized clinical trials.
On the other hand, where practical, the establishment of
multicenter consortia trials is strongly supported, with the
intention to provide enough statistical power for relevant
endpoints. We also support meta-analyses of existing trials
to obtain datasets of great enough magnitude to investigate questions that cannot be reliably addressed individually. It is very important that clinical trials have standard
nomenclature and reporting system (eg, using endpoints
and metrics that are consistent) so that they can be metaanalyzed. Trials that establish new and reliable biomarkers of organ viability should be strongly encouraged and
supported.
3.	Which preservation techniques should be compared in the
next randomized trials?

In the current era, with SCS the standard of care in
liver preservation, the group believe that novel perfusion
techniques should be compared with this before comparison between different perfusion methods. The majority
of published trials to date have been safety (phase 1) or
nonrandomized (phase 2) trials. These studies have effectively established the claims that can be made for the use
of these novel technologies; this is an essential prerequisite
in advance of RCTs designed to test efficacy. The results
of a number of properly powered randomized trials are
awaited: the results of these should provide the stimulus
to design trials to establish the relative merits of different perfusion methodologies. Logically, there will be trials
which compare NMP with HMP and NRP. However, there
will be numerous permutations to be considered, including
the variations of timing of perfusion (eg, continuous perfusion, post-SCS perfusion) and combinations of HMP and
NMP. The primary and secondary endpoints will be key to
the value of these trials. Health economic and logistic endpoints may prove as important as graft injury endpoints.
4. Which grafts should be included in clinical trials?

Preliminary studies, such as the majority of the singlearm studies carried out to date, have been designed for
proof of feasibility and safety, and therefore, have most
commonly enrolled livers that would be acceptable in current practice. Now, that the feasibility of perfusion is more
widely accepted, trials are addressing issues of efficacy. In

these trials, the enrollment criteria may be selective (eg,
DCD only) or general (eg, all organs). Although all grafts
may benefit from MP preservation, our recommendation
is to focus on extended-criteria grafts (DCD, older, steatotic grafts) in the next trials because these are the organs
that logically should have the greatest benefit. Indeed, it
is likely that financial and logistical constraints will likely
limit the use of perfusion to high-risk organs.44 Studies
that show cost-effectiveness of MP in high-risk organs
are important because this is the context in which higher
up-front costs may be associated with downstream cost
savings and broader acceptance of the technology, as the
potential to save money and increase organ utilization is
appreciated.52 The problem is that there is no standard
definition of extended-criteria donors, and such definition
would be important to compare clinical trials.
DISCUSSION
Limitations and Pitfalls of MP Trials

In general, transplant clinical trials are considered to be
of limited quality when compared with pharmacological
intervention trials.21,25,28,29 However, many of the flaws
of these studies can be prevented by well-designed trials.
There are several reasons for the compromised quality of
many of the trials that have been conducted in liver MP.
Different Nomenclature of Perfusion Settings/Lack
of Standardization

With the number of publications on liver MP to date
exceeding 450, the last 15 years have seen a significant
increase in the volume of both experimental and clinical liver MP preservation research.20 Several groups have
described different methods of MP with respect to temperature, the addition of oxygenation, and whether the
perfusion is flow or pressure controlled. It is very important to clearly describe perfusion settings (flow, pressure,
resistance), to correct for graft weight (eg, mL/min/100g),
temperature of perfusion, dual (PV+HA) versus single
perfusion, oxygen saturation, and partial pressure, composition of the perfusate, supplementation of therapeutic
agents, Varying definitions for reporting DCD data (eg,
functional warm ischemia) is also a source of inconsistencies among studies.
Because liver MP preservation is a relatively new technology with a wide variety of technical aspects continuing to be
explored by several groups worldwide, the publications on
MP have shown significant inconsistencies. These include the
nomenclature used to describe the different MP techniques
(abbreviations included), the temperatures considered to
be hypo-, subnormo-, or normothermic, and the details of
the methodology are reported. The lack of standardized
nomenclature and guidelines for reporting technical details
makes it difficult to reproduce experiments, compare different studies, and perform meta-analyses. With the number
of clinical studies on MP of donor livers rapidly increasing,
a team of international experts proposed a nomenclature
consensus and standardized set of guidelines for reporting
the methodology of future studies on liver MP.53 It is the
suggestion of our group that this nomenclature is adopted.
Whenever possible, investigators should agree on the
development of a “master design” of clinical trial for a
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more comprehensive analysis and to allow comparisons
among studies (eg, a standard set of specimens like perfusate, blood, bile, and tissue to be collected at predetermined timepoints). This would significantly increase the
power of subsequent laboratory analysis in helping find
biomarkers of viability.
Our group also recommended that study protocols
should be made public in advance in an open access registry of clinical studies (clinicaltrials.gov, EudraCT, ChiCTR)
or peer-reviewed publications.
Sample Size and Costs

Transplant clinical trials in general require a large number of individuals to be enrolled.23,38 For example, a proposed reduction in event incidence from 30% to 20%, with
2-sided type-I error probability of 0.05 and 80% power,
the estimated sample size necessary in each study arm is
294 without accounting for patients lost to follow-up.21
Small sample sizes are a common limitation in liver MP
clinical trials. Although single center, single-arm studies are
helpful to provide preliminary data, it is important to progress to multicenter and adequately powered randomized
trials as soon as the focus moves to efficacy. Very few, if
any, transplant units in the world have the case volume
needed to carry out randomized trials in organ preservation as a single center, and the need to collaborate in multicenter trials is therefore paramount.
As noted above, some of the drawbacks of underpowered single center retrospective trials might be overcome
by the creation of international or national data registries
for all machine perfused livers.54 This would be an ideal
resource to allow us to compare different techniques when
the right variables are collected, and the methodology is
standardized. With artificial intelligence or computerized
analysis of all biomarkers obtained during perfusion and
posttransplant, we may be able to create and validate viability criteria.
Decisions to adopt interventions at the policy level
depend not only on the evidence around their effects on
clinical outcomes but also on costs of care.52 Clinical trials involving MP are very expensive. Costs of acquisition
of the pump itself and the expensive disposable cassettes
required for each case are limiting for many institutions.
The necessary ties of such trials to industry potentially
create conflicts of interests,56 but these can be managed
by complete transparency and by ensuring that the trials
are run and data analyzed with independent oversight. MP
requires equipment that may cost hundreds of thousands
of dollars for the device itself, in addition to which there
are costs of disposables (as high as US $50 000 per graft),
and perfusate components.44 Trials that require initiation
of MP at the donor hospital can potentially add additional
logistical challenges and costs. An extra member of the
perfusion team is needed to set up and run the liver perfusion. Transporting the machine and additional personnel
can add to the complexity of the transportation logistics to
and from the donor hospital.44
Trial designs for liver MP must be intelligently restructured to ensure that the trial cost is reduced and the maximum amount of questions are reliably answered. There is
also opportunity to incorporate novel trial designs in MP
that would allow researchers to potentially test multiple
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hypotheses without the need for large and expensive trials using master protocols for new study designs—namely
platform, basket, and umbrella- or adaptive trial designs
(ATDs).38 Master protocols are novel designs that investigate multiple hypotheses through concurrent sub-studies
(eg, multiple treatments or populations or that allow adding/removing arms during the trial), offering enhanced
efficiency and a more ethical approach to trial evaluation.
It allows to evaluate multiple hypotheses, and the general
goals are improving efficiency and establishing uniformity
through standardization of procedures in the development
and evaluation of different interventions. Master protocols
may be tailored and adapted to suit the research objectives of multiple clinical indications, but master protocols
have not been well established in fields outside of oncology.56 It may be possible through a coordinated effort by
researchers, the pharmaceutical industry, and regulatory
bodies, that master protocols can be implemented in transplantation.38 They may feasible and especially important
when clinical trials involving target molecular therapy during machine preservation are implemented.57 For a literature review as a landscape analysis of master protocols,
please see Park et al.58 Other alternative is to use ATDs.
This is a methodology in which a clinical trial adapts as
the trial proceeds depending on the outcomes of patients
enrolled. The criteria for these decisions are set before the
beginning of the trial. An adaptive design is best used in
trials with short-term endpoints. Endpoints of ATDs can
be traditional clinical endpoints or surrogate endpoints
(biomarkers).
Appropriateness of Control Arms

The specific selection of a control arm is of critical
importance to the utility of an RCT and extrapolation
based on the assumed therapeutic benefits of other treatments not tested in the trial are invalid. In most cases,
the control arm of an RCT should represent the standard
of care. A standard of care may be defined as a national
authority approved regimen (as the Food and Drug
Administration in United States), a consensus based “most
common treatment” or the standard protocol utilized at
a particular center.21,45 In MP trials, controls have generally been standard static cold preservation (SCS) using
UW or HTK solution. However, there is increasing interest by the transplant community to compare different MP
techniques. In contrast to trials in paired organs (kidneys,
lungs), liver MP clinical trials have distinct challenges to
prove superiority, as there is no natural ideal control arm
(the paired organ). In liver preservation studies, therefore,
there are both donor and recipient confounding variables,
some of which might require stratification (eg, DBD/DCD
status, age, degree of steatosis), and all of which contribute
to the need for a larger sample size.
Nonblinding Nature of MP Trials

As a general principle of clinical trials, the blinding of
both patients and investigators to the treatment investigated is important to eliminate unconscious bias of data
reporting by both.59-61 In trials assessing nonpharmacological interventions (eg, surgical randomized clinical trials),
blinding is usually more difficult or impossible. A systematic review of surgical trials showed that blinding was
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explicitly stated for practitioners, patients, and outcome
observers in 3%, 37%, and 52%, respectively.62
Unfortunately, in clinical trials with liver MP, it is
extremely difficult for investigators (ie, the transplant
team) to be blinded; this constitutes an important limitation. This is intrinsic to the nature of the surgical procedure, as MP cannulation, and backtable preparation of
the allograft are usually performed by members of the
same team and MP often occurs in the same operating
room as the liver transplant procedure itself.63 MP can be
complex and requires surgeons (usually investigators) to
perform the backtable dissection, cannulation, and perfusion initiation. Due to the staffing limitations and availability at most transplant centers, it is difficult to replace
surgeons involved with the investigation with other surgeons or technicians not involved with the trial. Even if
this were not the case and a separate trial team carries out
the cannulation and perfusion, it is almost impossible for
the transplanting team to remain unaware of the arm to
which a particular liver belongs. It is vital therefore that as
far as possible, the endpoints of the trial should be based
on objective data-points and not vulnerable to subjective
observer bias. For example, a surgeon’s impression of the
quality of organ reperfusion is subjective (and therefore
a poor endpoint), whereas an anesthetist’s assessment of
the magnitude of the reperfusion syndrome, based on the
measured effect on blood pressure, can be objective (and
therefore a better endpoint).
Lack of Reliable Biomarker and The “Wash-Out”
Phenomenon

There is no reliable biomarker to predict clinical outcomes in liver transplantation. In most clinical and
experimental liver ex situ studies, posttransplant serum
transaminases or early allograft dysfunction (EAD)64 are
used as an injury marker to compare the quality of liver
preservation.20,46,47 The majority of clinical trials in liver
MP have also used EAD or transaminase peak as their primary end-point7 (Tables 2 and 3). It should be noted that
these endpoints have been used in the context of livers preserved by SCS but not confirmed in the context of MP.65,66
Perfusate transaminases (as opposed to postoperative
systemic levels of transaminase) have been used (typically in combination with graft lactate clearance and bile
production) during NMP to determine the viability of a
particular graft for implantation.1,7,48,67 Transaminase levels may be influenced by the age of the donor, steatosis,
ischemia time, among other factors. Perfusate transaminases should be normalized for liver weight and perfusate
volume to allow comparability with other perfusion systems and different livers.
There are several reasons why peak transaminases and
consequently EAD are not primary endpoints of choice
in a MP clinical trial. Evidence comes from a number of
sources:
1. Transaminase levels in acute hepatitis: In ischemic and
toxic hepatic injury, transaminase levels fall rapidly with
both recovery and necrosis; these are therefore a poor indicator of recovery.68 Serum transaminase levels do not correlate with survival in the context of acute autoimmune
hepatitis: indeed, in the study of Al-Chalabi et al patients
in the highest tertile of AST level had superior survival

2.

3.

4.

5.

(avoidance of liver transplantation or death) to those in the
lower tertiles, although it is notable that the latter patients
had higher incidences of cirrhosis. There was some correlation between histological necroinflammatory activity and
AST level.69
Transaminase levels following nontransplant liver resection surgery: In an analysis of 651 hepatic resections, of
which 58% underwent inflow occlusion, Boleslawski et al
showed that peak postoperative transaminase levels did
not correlate with duration of inflow occlusion or with
postoperative complications.70
Transaminase levels in the deceased liver donor: Donor
transaminase is a poor predictor of posttransplant graft
survival. Cuende et al analyzed data from 5150 liver transplants, showing no significant association between donor
peak transaminase and graft survival in a Cox regression
analysis.71 In a retrospective study of UNOS data (2007–
2016), Feng et al analyzed SRTR data from 20 023 liver
transplants, showing that donor AST levels were not an
independent predictor of graft outcome: donor AST level is
therefore not a component of the donor risk index calculation.72 Similarly, the Eurotransplant Donor Risk Index,
based on analysis of 5939 transplants, does not include
donor transaminase because this was not shown to be
a significant independent variable with respect to graft
survival.73 In a retrospective study of UNOS data on all
deceased donors liver transplants between 2007 and 2016
(n = 59 050), Kaltenbach et al categorized donors into
6 study groups according to peak ALT (<499, 500–749,
750–999, 1000–1999, 2000–2999, and >3000 IU/L). They
found evidence that preretrieval transaminase level does
not predict posttransplant outcome.74 Single center cases
series have reported successful transplants even when the
donor peak transaminases are extremely high.75-77
Posttransplant transaminase levels: There is evidence of an
association between peak levels and transplant outcome,
and this has been traditionally used as a surrogate endpoint
for liver preservation studies in clinical and experimental
transplantation. However, there is no linear correlation
between the levels of transaminases and poor outcomes.
Rosen et al showed the primary nonfunction rates were
significantly correlated with peak postoperative AST levels and 12-month graft survival when the AST was >2000
IU/L. The effect on 12-month patient survival was limited to patients with the most extreme AST levels (>5000
IU/L)—the difference in the effects on graft and patient survival being a function of Retransplantation.78 Eisenbach et
al analyzed 328 patients and demonstrated that high peak
levels of AST were significantly correlated to graft loss or
death.65 Robertson et al analyzed 1272 patients from a single institution, showing that AST levels correlate strongly
with early graft failure on day 3 and on day 7 postoperatively.66 Conversely, Gaffey et al correlating the peak of
AST and ALT with postop biopsy finding concluded that
transaminase levels are not useful in the diagnosis of preservation injury.79 Anecdotally, good graft function has been
reported even when the early posttransplant AST level was
as high as 17 600.80
Dilution and wash-out of transaminase: Postoperative
transaminase levels are likely to be influenced by the size
of the liver, the process of MP and volume of perfusate
(“wash-out” phenomenon).43,44,54,63 Most studies have not
normalized the transaminases by the liver weight. Organs
that are machine perfused either are flushed with a larger
amount of preservation solution (extra liters) or reperfused
and oxygenated leading to release of transaminases accumulated in the graft to the perfusion circuit (perfusate) and
not in the recipient immediately posttransplant. This leads
to different concentrations of metabolites and biomarkers
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such as cytokines, AST, and ALT in the graft at the time
of implantation, leading to different levels postoperative
(wash-out phenomenon). Because transaminases have a
long half-life (17 ± 5 h for AST, 47 ± 10 h for ALT),68,81 the
posttransplant transaminase levels in recipients of grafts
that were not machine perfused often have higher levels,
while recipients that received MP grafts have artificially or
“falsely” lower levels.43,44,54,63

Little is known about the early postoperative parameters that can be used as valid predictive indices for liver
transplant outcomes and several early posttransplant
tests and scores (composite endpoints) have been proposed.82 The most commonly used definition of EAD
was by Olthoff et al64 uses transaminase peak (AST or
ALT > 2000 IU/L) within the first 7 days, Bilirubin ≥10 mg/
dL on day 7, INR ≥ 1.6 on day 7, and is therefore prone to
bias. MEAF uses the same parameters as EAD by Olthoff
but the max value at the first 3 days. This score has been
shown to be more granular, with scores that varies from 0
to 10, and more reliable that EAD by Olthoff.83-85 There is
likely underestimation of EAD in MP livers due to lower
transaminase peak after passive release into the perfusate
after large volume of flush solution of liver grafts or active
release of transaminases into the perfusate after reoxygenation under normothermic temperature. The transaminase
peak usually happens in the first 24 hours posttransplant,
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affecting the EAD rate as well.86,87 To support this finding
of the influence of transaminases on EAD, in a large randomized study, Nasralla et al found that the difference in
EAD rate between MP and SCS preservation was largely
due to the transaminase values.50 Therefore, transaminases
peak and commonly used definition of EAD that takes into
account transaminases peak should preferably not be used
as a primary endpoint in MP trials.7,43,44,54,88 EAD likely
needs to be redefined, modeled, and validated in the setting
of machine preservation. Attempts to add other parameters
like platelet count or factor V as a biomarker of EAD have
been recently proposed.89,90 A new EAD formula involving both liver synthetic function and injury markers as a
continuum instead of a binary use as previously described
by Olthoff et al should address this limitation. In fact, the
newly proposed parameter, the L-GrAFT risk score, is
claimed to be highly accurate, predict 3-month graft failure posttransplant that is more accurate than existing EAD
and MEAF scores.89,91
Viability Markers Used During Machine Perfusion

Ex situ liver MP is believed to offer a platform to assess
viability of grafts before transplantation. They can be
assessed for appearance and consistency, hydro/hemodynamics, metabolic, and excretory function (Figure 1). NMP
is most commonly used to assess liver viability because the

FIGURE 1. Viability criteria proposed during liver machine perfusion. Hepatocyte function can be tested by evaluating hydro-/
hemodynamics (flow, resistance, and pressure), perfusate and bile composition, and other biomarkers. Cholangiocyte function (bile
duct) can be assessed by evaluating bile flow and composition. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN,
blood urea nitrogen.
Copyright © 2021 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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organ is maintained in a near-physiological state. Viability
testing during hypothermic machine perfusion (HMP) is
possible but more challenging since hepatic metabolism is
markedly reduced and bile production is minimal. There
is no consensus on the viability criteria, but the main candidates are perfusate lactate clearance, maintenance of a
physiological pH in the perfusate, maintenance of glucose
metabolism, bile production (if NMP), Bile pH, among
others.10,18,92-96 For viability assessment during HMP, the
only injury biomarker that has been proposed is real time
measurement of flavin mononucleotide (FMN), which is
released upon injury to mitochondrial complex I.96 There
are few clinical studies investigating viability assessment
during MP with promising results. However, there is to
date no randomized clinical study that validated these
criteria with posttransplant outcomes. This is of critical
importance because it is the only way to prove MP can reliably make nontransplantable organs transplantable.16,17,19
With artificial intelligence/machine learning analysis of
all biomarkers obtained during perfusion and posttransplant, we hope to create and validate more reliable viability criteria to predict EAD.
Selection Bias, Randomization, and Intention to
Treat Analysis

As with all clinical trials, it is essential to identify and
mitigate sources of selection bias in trials of perfusion
technology. There is a general presumption that clinical
trials are not susceptible to selection biases that are common to observational studies. However, selection biases
can have marked impact on the findings of clinical trials.21,25,28,60-62 There are several measures that we can take
when designing clinical trials (Table 4). The International
Committee of Medical Journal Editors recommends that
all journal editors require the registration of clinical trials in a public trials registry at or before the time of first
patient enrollment as a condition of consideration for
publication97 (Clinical trial registration. A statement from
the International Committee of Medical Journal Editors.
Available from: http://www.icmje.org/recommendations/
browse/publishing-and-editorial-issues/clinical-trial-registration.html). A detailed description of the trial in open
source platforms for trial registries preferably in English
language (clinicaltrials.gov, EudraCT, ISCRNT, and other
national registries) or, when possible, manuscript publication of study protocols98-100 would allow us to enhance
transparency of research, reduce publication bias, and prevent selective reporting of research outcomes.28,63
Common sources of selection bias in RCTs that can artificially increase treatment effects include poor application
or design of the allocation process and incomplete or lack
of blinding (discussed above). The proper time of randomization for MP depends on the objective of the study. For

example, if the primary intention is to assess superiority
of the preservation and compare posttransplant outcomes,
the randomization time should be after final organ acceptance (after graft assessment by the procuring surgeon and
liver biopsy). Randomization before final acceptance of
the graft might enable selection bias, although we recognize that this may create logistical challenges depending
on whether the trial design involves perfusion initiation at
the donor hospital or at the transplant center. Achieving
good outcomes with perfused grafts that were declined by
all other local centers does not necessarily mean that MP
was responsible for graft rescue or transplantability of the
organ. At this time, there are no definitive viability criteria
and the decision whether to transplant or discard a liver is
subjective and often dependent on the particular practices
of the transplant center itself.102 There are several reports
showing good outcomes with livers that were declined by
all other centers without machine preservation.101-106 The
primary disadvantage of randomization at the time of final
acceptance is that the perfusion device would need to be
transported to the donor center regardless of which study
arm the organ is randomized to in studies designed to initiate perfusion at the donor hospital. Alternatively, if the
objective of the study is to assess organ utilization, then
randomization should be done as early in the process as
possible, ideally at the time of the organ offer or even at
the time of listing the patient for transplant.
It is very important that the statistical analysis is based
on an intention to treat analysis. Intention to treat analysis
is a comparison of the treatment groups that includes all
patients as originally allocated after randomization. This
is the recommended method in superiority trials to avoid
any bias. An additional “as treated” analysis will give
some impression of the possible effect of “cross-over” allocation—grafts that were allocated to 1 group but treated
with the other protocol (eg, allocated to MP but coldstored because the MP machine was not available or not
functioning). We also recommend a detailed description of
all grafts that were discarded in each study arm (before or
after perfusion) or any equipment failure so that the trial
report can provide a narrative of every organ that has been
randomized: this is an important way to detect selection
bias (eg, the decision to exclude an organ from a trial may
be subject to investigator/clinician bias).
Reallocation of Grafts When the Accepting Center
Declines a Graft or the Intended Recipient Is No
Longer a Candidate for Transplant

Transplant centers and Organ Procurement Organizations
should develop a contingency plan to reallocate perfused liver
grafts to avoid allocation delays or graft discard if a perfused
liver cannot be used. This situation arises when the intended
recipient, who had consented to the trial, becomes ineligible

TABLE 4.

Review criteria for the analysis of quality of clinical trials (modified from J Schold JD200821)

-

Is there documentation on nonparticipants and characteristics of excluded subjects?
Is the method of randomization and allocation appropriate and well described?
Is the analysis conducted on an intention-to-treat or on-treatment basis?
Is the interpretation of the trial results concordant with the data, particularly for the primary end
Are all relationships of investigators, handlers, and analyzers of the study data third parties disclosed?
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TABLE 5.

ILTS SIG “DCD, Preservation and Machine Perfusion” 12 recommendations for conducting clinical trials in liver MP
preservation
ILTS SIG recommendations of the working group

1 Nomenclature standardization/Consensus (allow comparisons and meta-analysis) according to Karangwa et al.53
2 Pretrial registration of study protocol in public trial registries like (clinicaltrials.gov, EudraCT, others) and publication in peer-reviewed journals.
3 Preference of randomized trials and meta-analyses of existing trials. Preference to include ECD grafts (DCD, older, steatotic grafts). Support of trials
looking into organ viability criteria as well.
4 Randomization time should depend on the primary outcome:
- At the time of patient listing (to assess/compare organ utilization rate)
- At the time of organ offer (to assess/compare organ utilization rate)
- At final organ acceptance (after visualization/biopsy at the donor hospital): To assess/compare posttransplant outcomes
5 Support for multicenter consortia trials.
6 Creation of an international registry of all cases of machine perfusion/NRP in Liver transplant.
7 P reference to use of clinical data (1-y graft survival, 1-y patient survival, ITBL/biliary complication rates, LOS, ICU stay, AKI/HD need, overall
complication rate, costs, etc) as primary outcomes instead of surrogate laboratory endpoints (until there is a validated endpoint). Consideration of
mortality on the waitlist as endpoint.
8 Support for trials that compare specific MP techniques with standard preservation technique (static cold preservation) first before comparing different
MP techniques. Then, compare HMP with NMP/NRP.
9 Redefinition of Early allograft dysfunction (Validation of composite endpoints of EAD in MP trials).
10 Intention-to-treat analysis. Detailed description/report of every graft that was damaged/lost during MP.
11 Collection of biospecimen (perfusate, bile, liver, and bile duct). Postreperfusion protocol biopsies and assessment of IRI by standard damage scores
(eg, Suzuki for liver parenchyma, and Op den Dries/Hansen for Bile duct).117,118
12 Contingency plan. Back-up allocation system in case the primary team declines the graft after reperfusion because of graft performance or the
intended recipient of a perfused liver can not undergo transplant (avoid surprises and allocation delays).
References in this table include studies by Karangwa et al,53 Suzuki et al,117 and Op den Dries et al.118
AKI, acute kidney injury; DCD, donor after circulatory death; EAD, early allograft dysfunction; ECD, extended criteria donor; HMP, hypothermic machine perfusion; ICU, intensive care unit; ILTS, International
Liver Transplantation Society; IRI, ischemia-reperfusion injury; ITBL, ischemic type biliary injury; LOS, length of stay; MP, machine perfusion; NMP, normothermic MP; SIG, special interest group.

at or shortly before the planned start time of the transplant
because of pre or intraoperative hemodynamic instability of
discovery of findings that were not known in advance (eg,
intraoperative finding of advanced cancer). There may be
other instances in which the accepting program places the
organ on the perfusion device as part of the trial and then
declines it because of poor graft performance during the perfusion. If possible, the organ should be allocated according to
the standard organ allocation rules, to the next recipient on
the match run list even if not enrolled in the trial, or in a nonparticipating center (ie, not simply the next patient consented
in the trial). If the graft is being preserved using a still-experimental technology (not yet approved by regulatory authorities), the recipient would have to provide consent to receive
this graft and it may require ethical approval by the institutional review board. Centers enrolled in trials should address
the issue of reallocation with other centers in their allocation
area in advance to ensure that sharing protocols are already
in place to prevent delays in the organ reallocation process.54
As part of this, centers should agree whether the graft should
remain on perfusion until arrival in the other center or if it
should be repacked in standard cold static preservation.
Conflict of Interests and Relation With Industry

It is well known that any trial can be affected by conflicts of interest.55 Machine perfusion clinical trials are
very expensive, and some have been supported or partially
supported by industry. We acknowledge that the relationship of academic institutions with industry is important.
Conflicts of interest should be clearly stated, and the way
to do this is well established. The role of external (particularly commercial) parties on trial design and analysis

should be clearly stated, including holders of data and the
responsible parties for analysis, as these relationships have
the potential to impact study validity and interpretation.110
RECOMMENDATIONS
Our working group attempted to provide recommendations based on the GRADE methodology and acknowledge the current knowledge gap in this recent field. The
first guidelines proposal for MP trials was initiated by
the American Society of Transplant Surgeons’ (ASTS)
Standards Committee in 2018.54 Some of our recommendations overlap this report. After thorough analysis and
discussion, we concluded that we do not have all the elements to make recommendations based on the GRADE
methodology. However, based on expert opinion, our
working group proposed 12 recommendations (Table 5).
CONCLUSIONS
Machine perfusion preservation is a promising approach
in liver transplantation.12-14 In the last 10 years, many clinical trials in ex situ liver MP have been of limited quality and
with specific limitations and pitfalls.7,15,17,43 Many of these
flaws can be avoided in future studies by well-designed protocols. The majority of MP clinical trials have been underpowered and some do not have clinically significant primary
endpoints. Although some of the evidence is very promising,
there is clear need for more information from high quality and appropriately powered trials. Scores to predict EAD
need to be validated in the setting of liver MP trials. As we
are moving from an early phase to maturation phase, certain
key elements of the design and reporting of clinical trials in
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liver MP should be standardized. Standardization of data
collection and reporting will allow comparisons of trials
and meta-analysis. Optimum trial design and interpretation
of data will increase the quality of the output, contributing
to patient safety and advancing the field.
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APPENDIX
ILTS Special Interest Group “DCD, Preservation and Machine Perfusion”:
Chair: Paulo N. Martins MD, PhD, FAST, FEBS, FACS (Univ Massachusetts, United States) Vice-chair: Michael Rizzari
MD (Henry Ford Hospital, United States); Members: Magdy Attia MD (Leeds, United Kingdom) David Ghinolfi MD,
PhD (Pisa, Italy); Ina Jochmans MD, PhD (Leuven, Belgium) Rajiv Jalan MBBS, MD, PhD, FRCP, FRCPE, FAASLD.
University College London (United Kingdom) Peter Friend MD (Oxford, United Kingdom); Attendees of the smallersubgroup workshop: Dieter Broering, Al Faisal University, Riyadh, Saudi Arabia; Michael Grat, Medical University of
Warsaw, Warsaw, Poland; Jean Gugenheim and Zhiyong Guo, The First Affiliated Hospital, Sun Yat-sen University,
Guangzhou, China; Andrew Jacques, Kysela Marek, and Valeria Mas, School of Medicine the University of Tennessee
Health Science Center Memphis, TN; Damiano Patrono, University of Turin Medical School Hospital, Turin, Italy;
Daniele Dondossola, Fondazione IRCCS Ca’Granda, University of Milan Medical School Hospital, Milan, Italy; Elizabeth
Pomfret, Colorado University, Denver-Co, United States; Patricia Ruiz, Biocruces Bizkaia Health Research Institute. Liver
Transplantation Unit, Hospital Universitario Cruces, Bilbao, Spain; Sandra Spiritelli and Waldemar Patkowski, Medical
University of Warsaw, Warsaw, Poland.; Peter DeMuylder, Organ Recovery Systems, Zaventem, Belgium.; Rutger Ploeg,
University of Oxford, Oxford, England; Hynek Mergental, Queen Elizabeth Hospital, University Hospitals Birmingham
NHS Foundation Trust, Birmingham, United Kingdom; Invited Faculty (panel of experts): For a list of their biographie
please go to: https://wp-ilts-media.s3.amazonaws.com/wp-content/uploads/2020/01/29161208/02-Final-ILTS-Venice2020-Meet-The-Faculty.pdf; Faculty listed in alphabetic order of last name: Peter L. Abt, MD, Hospital of the University
of Pennsylvania, Philadelphia, PA; Magdy Attia, MD, MS, FRCSGen, MBBCh, Leeds Teaching Hospitals, Leeds, United
Kingdom; PIERRE-A. CLAVIEN, MD, PhD, FACS, ASA, FRCS, FRCS, University Hospital Zurich, Zurich, Switzerland;
Miriam Cortes Cerisuelo, MD, PhD, King’s College Hospital, London, United Kingdom; Kristopher P. Croome,
MD, Mayo Clinic, Jacksonville, Florida, FL; Olivier Detry, MD, PhD, University of Liege, Liege, Belgium; Federica
Dondero Pozzo, MD, Beaujon Hospital, Paris, France; Philipp Dutkowski, MD, FEBS, University Hospital Zurich,
Zurich, Switzerland; David Foley, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI;
Constantino Fondevilla, MD, PhD, Hospital Clínic, Barcelona, Spain; Juan Carlos García-Valdecasas Salgado, MD, PhD,
Hospital Clinic University of Barcelona, Barcelona, Spain; Mikel Gastaca, MD, Cruces University Hospital, Bilbao,
Spain; Davide Ghinolfi, MD, PhD, Universita di Pisa, Pisa, Italy; James Guarrera, MD, FACS, New Jersey Medical School,
Newark, NJ; Zhiyong Guo, MD, PhD, Hospital of Sun Yat-sen University, Guangzhou, China; Nigel Heaton, MD,
FRCS, King’s College Hospital, London, United Kingdom; Roberto Hernandez-Alejandro, MD, University of Rochester
Medical Center, Rochester, NY; Amelia Hessheimer, MD, Hospital Clínic, Barcelona, Spain; Rajiv Jalan MD, PhD, MBBS,
FRCPE, FRCP, FAASZD, University College London, London, United Kingdom; Ina Jochmans, MD, PhD, University
Hospitals Leuven, Leuven, Belgium; Marit Kalisvaart, MD, PhD, University Hospital Zurich, Zurich, Switzerland;
Daniel Maluf, MD, UT/Methodist Transplant Institute Memphis, Memphis, TX; Paulo Martins, MD, PhD, The University
of Massachusetts Medical School, Worcester, MA; Eduardo Miñambres, MD, PhD, Hospital Universitario Marques de
Valdecilla, Santander, Spain; Paolo Muiesan, MD, The Queen Elizabeth Hospital, Birmingham, United Kingdom; David
Nasralla, BMBCh, MA, MRCS, University of Oxford, Oxford, United Kingdom; Gabriel Oniscu, MD, Royal Infirmary of
Edinburgh, Edinburgh, United Kingdom; Jacques Pirenne, MD, MSc, PhD, UZ Gasthuisberg, Leuven, Belgium; Wojciech
Polak, MD, PhD, Erasmus MC, Rotterdam, The Netherlands; Robert J. Porte, MD, PhD, FEBS, University Medical Center
Groningen, Groningen, The Netherlands; Cristiano Quintini, MD, Cleveland Clinic, Cleveland, OH; Michael Rizzari,
MD, Henry Ford Transplant Institute, Detroit, MI; Eric Savier, MD, University Hospital Pitié-Salpetrière, Paris, France;
Andrea Schlegel, MD, The Queen Elizabeth Hospital, Birmingham, United Kingdom.; C. Burcin Taner, MD, FACS, Mayo
Clinic Florida.; Christopher J.E. Watson, MD, Cambridge University Hospitals, Cambridge, United Kingdom.
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